Anorexia News and Research

RSS

Patients with body dysmorphic disorder have less brain activity in visual processing

People suffering from body dysmorphic disorder, or BDD - a severe mental illness characterized by debilitating misperceptions that one appears disfigured and ugly - process visual information abnormally, even when looking at inanimate objects, according to a new UCLA study.

27 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Study shows why individuals with anorexia nervosa have paradoxical response to food

Perhaps the most puzzling symptom of anorexia nervosa - a disorder that tends to occur in young women - is the refusal to eat, resulting in extreme weight loss. While most people have a great deal of difficulty in dieting and losing weight, particularly if a diet extends over many months or years, individuals with anorexia nervosa can literally diet themselves to death. In fact, this disorder has a very high death rate from starvation.

21 May 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

21 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

Caring Online offers comprehensive and informative website on adult eating disorders

Are you aware that eating disorders affect more than 10 million people in this country, and that bulimia, anorexia, binge eating and other destructive food behaviors are not exclusive to the youth? These serious and often deadly afflictions have become a growing problem with midlife adults and older, often more difficult to detect as adults are expected to have it "all together."

19 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Eating disorders - hitting early and hard

Children as young as seven have been admitted to hospitals for eating disorders. A peak support group has reported a doubling of calls about children under the age of 12 in the past decade. Being hit so early with these disorders also means malnutrition leading to retarded growth, osteoporosis, infertility and changes in brain structure say experts.

30 Mar 2011

Eating disorders tough to conquer

Young people and adolescents have been repeatedly warned regarding eating disorders. Lisa Harmon Mollicone, coordinator of the Manalapan-Englishtown Community Alliance for the Prevention of Alcohol and Drug Abuse, addressed the topic of eating disorders at a full house during the Dec. 14 meeting of the alliance, held at the Manalapan Senior Center.

29 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Prevalence of eating disorders higher than previously thought

A new study shows that many American adolescents suffer from an eating disorder and struggle with related psychiatric disorders, including suicidal tendencies. The researchers write, “The prevalence of these disorders is higher than previously expected in this age range, and the patterns of [co-existing illnesses], role impairment and suicidality indicate that eating disorders represent a major public health concern.” Led by Sonja A. Swanson, of the National Institute of Mental Health, the research team reported the findings online March 7 in the Archives of General Psychiatry.

7 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

New study: Cannabis ingredient can improve appetites and sense of taste in cancer patients

The active ingredient in cannabis can improve the appetites and sense of taste in cancer patients, according to a new study published online in the cancer journal, Annals of Oncology today.

23 Feb 2011

Anorexia News and Research

Patients with body dysmorphic disorder have less brain activity in visual processing

FDA approves SUTENT for treatment of pancreatic NET

Study shows why individuals with anorexia nervosa have paradoxical response to food

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Caring Online offers comprehensive and informative website on adult eating disorders

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Lead investigator to discuss growing impact of AFib on US health care costs and resources

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Millennium submits two VELCADE sNDAs to FDA

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Eating disorders - hitting early and hard

Eating disorders tough to conquer

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Prevalence of eating disorders higher than previously thought

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

New study: Cannabis ingredient can improve appetites and sense of taste in cancer patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News